Personalized cancer therapy—leveraging a knowledge base for clinical decision-making

od Dumbrava, Ecaterina Ileana, Meric-Bernstam, Funda
izdano v Cold Spring Harb Mol Case Stud (2018)

Hypopigmented skin lesions on immunotherapy

od Dumbrava, Ecaterina Ileana, Ivan, Doina, Subbiah, Vivek
izdano v JAMA Oncol (2018)

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss

od Owusu-Brackett, Nicci, Zhao, Ming, Akcakanat, Argun, Evans, Kurt W., Yuca, Erkan, Dumbrava, Ecaterina Ileana, Janku, Filip, Meric-Bernstam, Funda
izdano v Oncotarget (2020)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer

od Owusu-Brackett, Nicci, Evans, Kurt W., Akcakanat, Argun, Yuca, Erkan, Tapia, Coya, Rizvi, Yasmeen Qamar, Dumbrava, Ecaterina Ileana, Janku, Filip, Meric-Bernstam, Funda
izdano v Oncotarget (2019)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

od Subbiah, Vivek, Dumbrava, Ecaterina Ileana, Jiang, Yunfang, Thein, Kyaw Z., Naing, Aung, Hong, David S., Fu, Siqing, Piha-Paul, Sarina A., Tsimberidou, Apostolia M., Janku, Filip, Meric-Bernstam, Funda, Kurzrock, Razelle, Falchook, Gerald
izdano v Exp Hematol Oncol (2020)

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

od Pairawan, Seyed, Zhao, Ming, Yuca, Erkan, Annis, Allen, Evans, Kurt, Sutton, David, Carvajal, Luis, Ren, Jian-Guo, Santiago, Solimar, Guerlavais, Vincent, Akcakanat, Argun, Tapia, Coya, Yang, Fei, Bose, Priya Subash Chandra, Zheng, Xiaofeng, Dumbrava, Ecaterina Ileana, Aivado, Manuel, Meric-Bernstam, Funda
izdano v Breast Cancer Res (2021)